JKJens König

Jens König

*This is an algorithmically generated author record based on publicly available information.

Jens König has a total of 228 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • RNA interference medication and transplantation procedures in patients with primary hyperoxaluria type 1

    by Cristina Martin-Higueras, Lodovica Borghese, Jens König, Caroline Kempf, Britta Höcker, Henry Fehrenbach, Adam Walli, Mark Born, Katharina Linden, Bernd Hoppe

    Background and hypothesis: Defective hepatic alanine-glyoxylate aminotransferase (AGT) leads to oxalate overproduction in primary hyperoxaluria type 1 (PH1). Nedosiran and lumasiran are RNA interference (RNAi) agents inhibiting oxalate production. In PH1 patients with kidney failure, isolated kidney transplantation (iKTx) might be possible with RNAi medication. Methods: We report on 17 PH1 patients on hemodialysis, who received lumasiran (7 patients, 1–68 years, 6 females), lumasiran post-nedosiran (2 patients, both 6.5 years, male), double RNAi (dRNAi) (4 patients, 37 years, 3 infants, all male) and nedosiran (4 patients, 11–58 years, 2 female). Plasma oxalate (Pox) pre-HD was measured and systemic oxalate grading (SOG) was evaluated mainly by bone magnetic resonance imaging and speckle echocardiography, before the start of and repeatedly during treatment. Results: In four patients iKTx was performed, being successful or with recurrence in two patients each. In others, development of Pox values under RNAi treatment and thus SOG increment and clinical deterioration were profound arguments for transplant decisions. Based on that, iKTx is now planned in five and liver/kidney Tx in four patients (one liver already transplanted). Three patients have died. Conclusion: Pox should not be the sole parameter by which to decide on Tx procedure. In patients with minor oxalate deposition, no SOG deterioration and sensitivity to vitamin B6 or under efficacious RNAi treatment, iKTx can be considered. Severe (and deteriorating) systemic oxalosis, high Pox during RNAi treatment and maximum dialysis should lead to reconsidering combined or sequential LKTx rather than iKTx. Patients with severe systemic oxalosis at time of diagnosis still have a high mortality rate.


  • Open Access

    Systematic review of outcomes reported in clinical research on nephronophthisis: how do they align with SONG Kids priorities?

    by Mareike Dahmer-Heath, Sven Optenhövel, Tanja Hechler, Martin Konrad, Jens König

    Background: Nephronophthisis (NPH) is a rare hereditary cystic kidney disease, characterized by a highly variable clinical and genetic presentation, accounting for up to 10% of kidney failure in children. Despite advances in understanding its molecular basis and phenotypic spectrum, no causative therapies exist, and clinical trials remain absent. To support future treatment development, patient-reported outcome measures (PROMs) tailored to NPH should be defined to prioritize outcomes meaningful to patients and families. Objectives: This study aimed to analyze the use of clinical data, surrogate parameters, and patient-reported outcomes in NPH research to date, with a focus on the Standardized Outcomes in Nephrology (SONG) project outcomes validated for children with chronic kidney disease (SONG Kids). Data sources: A systematic search of the MEDLINE database was conducted for NPH studies. Study eligibility criteria: Studies published after 1988, written in English, reporting at least one human clinical outcome, with a sample size of n ≥ 4, and using original data were considered eligible. Results: A total of 1066 records were retrieved through the search, of which 821 full-text reports were assessed for eligibility. Of these, 90 studies met eligibility criteria and were included in the review. While 100% of the studies reported clinical outcomes and 85% included surrogate parameter, only 41% examined patient-reported outcomes. Overlap between the SONG Kids outcome set and the outcomes identified in this study was moderate. Only 20 studies reported more than one SONG core outcome, while 24% and 66% of studies reported at least one middle tier or outer tier outcome, respectively. None of these studies used instruments validated for NPH. Limitations: The majority of studies focused primarily on molecular and genetic aspects, with clinical outcomes addressed only as a secondary consideration. The review incorporated only one prospective study, while the remaining studies were retrospective in nature. Differentiation between outcomes reported by children and those reported by parents was not possible in the included studies; this important distinction must be taken into account in the development of future PROMs for NPH. Conclusions and implications of key findings: Studies in NPH addressed both clinical outcomes and surrogate parameters, but there is a notable absence of measures related to life participation and patient-reported outcomes. Disease group-specific instruments fall short in adequately reflecting the symptoms of individual diseases, emphasizing the necessity for the development of disease-specific PROMs for NPH. Open Science Framework (OSF) registration: https://doi.org/10.17605/OSF.IO/658BR Graphical


  • Open Access

    Association of intrapatient tacrolimus variability and concentration-to-dose ratio with outcomes in pediatric kidney transplantation

    by Maral Baghai Arassi, Nora Fisch, Manuel Feißt, Kai Krupka, Britta Höcker, Alexander Fichtner, Nele Kanzelmeyer, Jens König, Anette Melk, Jun Oh, et al.

    Background: Data on the relevance of tacrolimus intrapatient variability (TacIPV) and concentration-to-dose ratio (C/D ratio) as an approximation of tacrolimus metabolism for predicting outcomes in pediatric kidney transplant (pKTx) recipients are scarce. Methods: We conducted a multicenter retrospective study of 255 pKTx recipients from the CERTAIN registry. TacIPV was quantified as the coefficient of variation (CV%) during months 6–12 post-transplant. In addition, the C/D ratio, corrected for body surface area, was calculated for the first 6 months post-transplant. Cutoffs were determined by minimization of log-rank P values: 23% for TacIPV and 1.0 for C/D ratio. Rejection episodes were classified according to the Banff criteria in the period following marker quantification. Results: A total of 13,159 tacrolimus trough blood levels were analyzed, with a median of 52 (IQR, 41–63) measurements per patient. High TacIPV (> 23%) during months 6–12 post-transplant was associated with an increased risk of rejection beyond 12 months post-transplant (hazard ratio (HR) 1.04, 95% CI 1.01–1.06, P = 0.002; Kaplan–Meier analysis P = 0.002). Similarly, a low C/D ratio (< 1.0), i.e., rapid tacrolimus metabolism, during the first 6 months was associated with a higher risk of rejection between months 6 and 12 (inverse HR 3.13, 95% CI 1.01–9.09, P = 0.04; Kaplan–Meier analysis P = 0.011). Conclusions: This largest to date multicenter study determines pediatric-specific cutoff values for TacIPV and tacrolimus C/D ratio as a predictive marker for graft rejection. Patients with these risk factors should be closely monitored and their immunosuppressive therapy adjusted accordingly. Graphical


  • Open Access

    Urinary Dickkopf-3 Reflects Disease Severity and Predicts Short-Term Kidney Function Decline in Renal Ciliopathies

    by Mareike Dahmer-Heath, Joachim Gerß, Danilo Fliser, Max Christoph Liebau, Thimoteus Speer, Anna-Katharina Telgmann, Kathrin Burgmaier, Petra Pennekamp, Lars Pape, Franz Schaefer, et al.


  • Open Access

    Incidence, risk factors, management strategies, and outcomes of antibody-mediated rejection in pediatric kidney transplant recipients—a multicenter analysis of the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN)

    by Alexander Fichtner, Laura Gauché, Caner Süsal, Thuong Hien Tran, Rüdiger Waldherr, Kai Krupka, Isabella Guzzo, Andrea Carraro, Jun Oh, Matthias Zirngibl, et al.

    Background: This study by the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN) was designed to determine the incidence, risk factors, current management strategies, and outcomes of antibody-mediated rejection (ABMR) in pediatric kidney transplant recipients (pKTR). Methods: We performed an international, multicenter, longitudinal cohort study of data reported to the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN) registry. Three hundred thirty-seven pKTR from 21 European centers were analyzed. Clinical outcomes, including kidney dysfunction, rejection, HLA donor-specific antibodies, BK polyomavirus-associated (BKPyV) nephropathy, and allograft loss, were assessed through 5 years post-transplant. Results: The cumulative incidence of de novo donor-specific class I HLA antibodies (HLA-DSA) post-transplant was 4.5% in year 1, 8.3% in year 3, and 13% in year 5; the corresponding data for de novo class II HLA-DSA were 10%, 22.5%, and 30.6%, respectively. For 5 years post-transplant, the cumulative incidence of acute ABMR was 10% and that of chronic active ABMR was 5.9%. HLA-DR mismatch and de novo HLA-DSA, especially double positivity for class I and class II HLA-DSA, were significant risk factors for ABMR, whereas cytomegalovirus (CMV) IgG negative recipient and CMV IgG negative donor were associated with a lower risk. BKPyV nephropathy was associated with the highest risk of graft dysfunction, followed by ABMR, T-cell mediated rejection, and older donor age. Conclusions: This study provides an estimate of the incidence of de novo HLA-DSA and ABMR in pKTR and highlights the importance of BKPyV nephropathy as a strong risk factor for allograft dysfunction. Graphical


  • Zystische Nierenerkrankungen im Kindesalter

    by Jens König, Max Christoph Liebau

  • Open Access

    Immunofluorescence analyses of respiratory epithelial cells aid the diagnosis of nephronophthisis

    by Carlotta Hellmann, Kai Wohlgemuth, Petra Pennekamp, Sebastian George, Mareike Dahmer-Heath, Martin Konrad, Heymut Omran, Jens König, for the NEOCYST Consortium, C. Bergmann, et al.

    Background: Nephronophthisis (NPH) comprises a heterogeneous group of inherited renal ciliopathies clinically characterized by progressive kidney failure. So far, definite diagnosis is based on molecular testing only. Here, we studied the feasibility of NPHP1 and NPHP4 immunostaining of nasal epithelial cells to secure and accelerate the diagnosis of NPH. Methods: Samples of 86 individuals with genetically determined renal ciliopathies were analyzed for NPHP1 localization using immunofluorescence microscopy (IF). A sub-cohort of 35 individuals was also analyzed for NPHP4 localization. Western blotting was performed to confirm IF results. Results: NPHP1 and NPHP4 were both absent in all individuals with disease-causing NPHP1 variants including one with a homozygous missense variant (c.1027G > A; p.Gly343Arg) formerly classified as a “variant of unknown significance.” In individuals with an NPHP4 genotype, we observed a complete absence of NPHP4 while NPHP1 was severely reduced. IF results were confirmed by immunoblotting. Variants in other genes related to renal ciliopathies did not show any impact on NPHP1/NPHP4 expression. Aberrant immunostaining in two genetically unsolved individuals gave rise for a further genetic workup resulting in a genetic diagnosis for both with disease-causing variants in NPHP1 and NPHP4, respectively. Conclusions: IF of patient-derived respiratory epithelial cells may help to secure and accelerate the diagnosis of nephronophthisis—both by verifying inconclusive genetic results and by stratifying genetic diagnostic approaches. Furthermore, we provide in vivo evidence for the interaction of NPHP1 and NPHP4 in a functional module. Graphical


  • Top Cited Papers
    Open Access

    Bardet-Biedl syndrome improved diagnosis criteria and management: Inter European Reference Networks consensus statement and recommendations

    by Hélène Dollfus, Marc R. Lilien, Pietro Maffei, Alain Verloes, Jean Muller, Giacomo M. Bacci, Metin Cetiner, Erica L. T. van Den Akker, Monika Grudzinska Pechhacker, Francesco Testa, et al.

    Four European Reference Networks (ERN-EYE, ERKNet, Endo-ERN, ERN-ITHACA) have teamed up to establish a consensus statement and recommendations for Bardet-Biedl syndrome (BBS). BBS is an autosomal recessive ciliopathy with at least 26 genes identified to date. The clinical manifestations are pleiotropic, can be observed in utero and will progress with age. Genetic testing has progressively improved in the last years prompting for a revision of the diagnostic criteria taking into account clinical Primary and Secondary features, as well as positive or negative molecular diagnosis. This consensus statement also emphasizes on initial diagnosis, monitoring and lifelong follow-up, and symptomatic care that can be provided to patients and family members according to the involved care professionals. For paediatricians, developmental anomalies can be at the forefront for diagnosis (such as polydactyly) but can require specific care, such as for associated neuro developmental disorders. For ophthalmology, the early onset retinal degeneration requires ad hoc functional and imaging technologies and specific care for severe visual impairment. For endocrinology, among other manifestations, early onset obesity and its complications has benefited from better evaluation of eating behaviour problems, improved lifestyle programs, and from novel pharmacological therapies. Kidney and urinary track involvements warrants lifespan attention, as chronic kidney failure can occur and early management might improve outcome. This consensus recommends revised diagnostic criteria for BBS that will ensure certainty of diagnosis, giving robust grounds for genetic counselling as well as in the perspective of future trials for innovative therapies.


  • Zystische Nierenerkrankungen

    by Max C. Liebau, Jens König, Silke Riechardt, Stefan Gförer